medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2014, Number 6

<< Back Next >>

Salud Mental 2014; 37 (6)

Validez de la Escala de Evaluación Cognitiva de Montreal (MoCA) para determinar deterioro cognitivo en pacientes con esquizofrenia

Rodríguez-Bores RL, Saracco-Álvarez R, Escamilla-Orozco R, Fresán OA

Language: Spanish
References: 35
Page: 517-522
PDF size: 249.89 Kb.


ABSTRACT

Background. Schizophrenia is a severe mental disorder characterized by complex symptoms and impaired cognitive function, which has been considered a core feature. Research into cognition and schizophrenia over the past years has taken several different approaches including psychometric assessments.
Objective. The Montreal Cognitive Assessment (MoCA) has been proven useful in detecting cognitive impairment in patients with several forms of dementia. Our aim was to assess its validity as a screening instrument for cognitive impairment in schizophrenic patients.
Material and methods. One hundred patients with diagnosis of schizophrenia were recruited at the Schizophrenia Clinic of the National Institute of Psychiatry in Mexico. The MoCA and MMSE were used to assess cognitive functions in these patients. For the concurrent validity, the MoCA, MMSE and PANSS were used, and existing methods were utilized to determine reliability and validation.
Results. According to the MMSE-education adjusted cut-off scores, only 8% of the patients in our sample were found with cognitive impairment in contrast with 69% of the total score obtained from the MoCA. The MoCA was tested for reliability with a Cronbach’s alpha=0.71 similar to the one reported for MMSE (α=0.70) showing appropriate concurrent validity.
Conclusions. The MoCA is a cognitive tool with adequate psychometric properties as a screening instrument for the detection of mild cognitive impairment in schizophrenia. It also promises to fill an urgent unmet need for a brief screening tool capable of detecting patients with MCI and schizophrenia.


REFERENCES

  1. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15(4):399-409.

  2. Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009;18(1):23-33.

  3. Malla AK, Norman RM, Joober R. First-episode psychosis, early intervention, and outcome: what have we learned? Can J Psychiatry 2005;50(14):881-891.

  4. Black K, Peters L, Rui Q, Milliken H et al. Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophr Res 2001;47(2-3):215-222.

  5. Stirling J, White C, Lewis S, Hopkins R et al. Neurocognitive function and outcome in first episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res 2003;65:75-86.

  6. Galinska B, Szulc A, Czernikiewicz A. Duration of untreated psychosis in first-episode schizophrenia: clinical and cognitive correlates. Psychiatr Pol 2005;39(5):859-868.

  7. Harvey PD, Geyer MA, Robbins TW, Krystal JH. Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology (Berl) 2003;169(3-4):213-214.

  8. Folstein M, Folstein S, MCHugh PR. Minimental State: a practical method for grading cognitive state of the patients for the clinican. J Psychiatr Res 1975;12:189-198.

  9. Crum M, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. J American Medical Association 1993;269(18):2386-239.

  10. Thal LT, Grundmen M, Golden R. Alzheimer diseases: a correlational analyses of the Blessed information memory concentration test and the Minimental State. Exam Neurology 1986;36:262-264.

  11. Feher EP. Establishing the limits of the Minimental State examination of substensts. Arch Neurol 1992;49:87-92.

  12. Pendlebury ST, Cuthbertson FC, Welch SJV, Mehta Z, Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 2010;41:1290–1293. Rodríguez-Bores Ramírez et al. 522 Vol. 37, No. 6, noviembre-diciembre 2014

  13. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53(4):695-699.

  14. Berman I, Viegner B, Merson A, Allan E et al. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 1997;25(1):1-10.

  15. Hofer B, Niedermayer G, Kemmler MA, Rettenbacher E et al. Trebo, C.G. Widschwendter, W.W. Fleischhacker Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr Res 2007;126–131.

  16. Cameron AM, Oram J, Geffen GM, Kavanagh DJ et al. Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res 2002;110(1):49-61.

  17. Rodríguez-Jiménez R, Bagney A, Mezquita L, Martínez-Gras I et al. PARG. Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. Schizophr Res 2013;143(1):77-83.

  18. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;(19):1717-725.

  19. Roalf DR, Moberg PJ, Xie SX, Wolk DA et al. Comparative accuracies of two common screening instruments for classification of Alzheimer’s disease, mild cognitive impairment, and healthy aging. Alzheimers Dement 2013;(5):529-537.

  20. Yokomizo JE, Simon SS, De Campos Bottino CM. Cognitive screening for dementia in primary care: a systematic review. Int Psychogeriatr 2014;15:1-22.

  21. Fisekovic S, Memic A, Pasalic A. Correlation between MoCA and mmse for the assessment of cognition in schizophrenia. Acta Inform Med 2012;20(3):186-189.

  22. Arunpongpaisal S, Sangsirilak A. Using MoCA-Thai to evaluate cognitive impairment in patients with schizophrenia. J Med Assoc Thai 2013;96(7):860-865.

  23. American Psychiatric Association (APA). Manual Diagnóstico y Estadístico de los Trastornos Mentales DSM-IV-tr. Barcelona: Masson; 2002.

  24. Kay S, Fisbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.

  25. Lancon C, Auqioer P, Nayt G, Reine G. 2000. Stability of the five-factor structure of the Positive and Negative syndrome Scale (PANSS). Schizophr Res 2002;42:231–239.

  26. Fresán A, De la Fuente-Sandoval C, Loyzaga C, García-Anaya M et al. A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. Schizophr Res 2005;72(2-3):123-129.

  27. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000;26(1):119-136.

  28. Ziv I, Leiser D, Levine J. Social cognition in schizophrenia: cognitive and affective factors. Cogn Neuropsychiatry 2011;16(1):71-91.

  29. Evans JD, Heaton RK, Paulsen JS, Palmer BW et al. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry 2003;53(5):422-430.

  30. Apiquián–Guitart R, Fresán–Orellana A, García–Anaya M, Lóyzaga– Mendoza C et al. Impacto de la duración de la psicosis no tratada en pacientes con primer episodio psicótico. Estudio de seguimiento a un año. Gac Méd Méx 2000;142(2).

  31. Petersen RC, Doody R, Kurz A, Mohs RC et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58(12):1985-92.

  32. Woodberry KA, Giuliano AJ et al. Premorbid IQ in schizophrenia: A meta-analytic review. Am J Psychiatry 2008;165:579–587.

  33. Duro D, Simões MR, Ponciano E, Santana I. Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. J Neurol 2010;257(5):728-734.

  34. Pendlebury ST, Cuthbertson FC, Welch SJ, Mehta Z et al. Underestimation of cognitive impairment by mini-mental state examination versus the montreal cognitive assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 2010;(6):1290-1293.

  35. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75(19):1717-1725.




2020     |     www.medigraphic.com